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ECONOMICS OF TRANSFUSION
Yeh JM1, Botteman MF2, Pashos CL1, Postma MJ3,
Staginnus U4
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Despite recent advances in blood screening techniques,
transfusions are not risk-free. Therefore, screening for
viral and bacterial infections as well as other, newly-
emerging agents continues to attract attention in the
medical and health policy communities. At the same 
time, governments and other decision-making bodies
increasingly use cost-effectiveness analyses to justify (or
reject) allocation of limited ﬁnancial resources to new
technologies.
OBJECTIVES: To assess the cost-effectiveness of com-
monly employed blood safety interventions, and compare
those cost effectiveness levels with other accepted injury
prevention measures.
METHODS: Using MEDLINE, we conducted a literature
review on the cost-effectiveness of various transfusion-
relevant blood safety interventions. We identiﬁed 16
studies (published between 1993 and 2000) of blood
safety interventions that evaluated their economic beneﬁt
as either a cost per QALY or cost per life year (LY). These
interventions included several testing procedures for
transfusion donations (such as viral screening procedures
for HIV) and medical procedures (such as autologous
blood transfusion in elective surgery and epoietin
therapy). Most technologies related to testing and pro-
cessing blood donations are now standard practice in the
USA and Europe.
RESULTS: A majority of blood safety interventions had
cost-effectiveness ratios greater than $200,000 per QALY
or LY. Fewer than 35% had cost-effectiveness ratios less
than $50,000 per QALY or LY.
CONCLUSIONS: Many blood safety and injury preven-
tion regulations have cost-effectiveness ratios well above
$50,000 per QALY. Although $50,000 per QALY is 
recognized as the standard threshold value against 
which medical technologies are evaluated, many com-
monly accepted blood safety interventions and injury pre-
vention measures have much higher cost effectiveness
ratios. This indicates that society places a high value on
the risks prevented or reduced by such measures and sug-
gests that innovative blood safety technologies should be
assessed against a higher cost-effectiveness threshold.
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ANALYZING THE CLINICAL, ECONOMIC,AND
POLICY IMPACT OF INDIVIDUALIZED
MEDICINE BASED ON GENETIC INFORMATION
(“PHARMACOGENOMICS”)
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OBJECTIVES: The Human Genome Project has the
potential to revolutionize every aspect of pharmaceutical
science and the pharmaceutical industry. Pharmaco-
genomics is a new discipline with the goal of under-
standing the genetic basis for how individuals differ in
their response to drugs. However, there has not been a
systematic review of what is known about the societal
implications of these developments. Our objective is to:
(1) develop a framework for reviewing the clinical, eco-
nomic, and policy implications of pharmacogenomics,
and (2) systematically review the literature to assess what
is currently known about these issues.
METHODS: Our analysis builds on our previous sys-
tematic review of the impact of pharmacogenomics on
adverse drug reactions. We used systematic literature
review and data gathering to develop the framework and
to assess the literature.
RESULTS: We developed a framework that examines 
the implications of using pharmacogenomics from three
views: (1) Perspective (basic science, clinical, or policy
science), (2) Approach (drug development, drug substitu-
tion, or genotyping), and (3) Stakeholders (patients,
providers, industry, payers, government, or society). We
found that there are many existing gaps in the literature
examining these issues. Much of the literature has focused
on the use of genetic information to predict disease 
risk, such as genetic predisposition for breast cancer, but
these studies often do not address the relevant issues for
pharmacogenomics.
CONCLUSIONS: Only a few studies have begun to
address the economic impact of introducing genotyping
as a guide for individual therapy and the implications 
for health care provision and ﬁnancing. It will thus be
critical to conduct cost-effectiveness analyses and other
evaluations of the clinical, economic, and policy impact
of pharmacogenomics.
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COST EFFECTIVENESS ANALYSIS OF
PHARMACEUTICAL CARE IN A MEDICARE
DRUG BENEFIT PROGRAM
Etemad LR, Hay JW
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: There has been substantial interest in 
a Medicare drug beneﬁt program. Little attention has
focused on ensuring improved access to medication mon-
itoring for Medicare beneﬁciaries. Using a societal per-
spective, we evaluated the impact pharmacists could have
on inappropriate prescribing, patient compliance and
medication-related morbidity and mortality within a
Medicare Drug Beneﬁts program.
METHODS: To the extent possible, the cost-effectiveness
modeling followed the methodology guidelines of the US
Public Health Service Task Force on Cost Effectiveness
Analysis. Data sources and model parameters were iden-
tiﬁed by conducting a comprehensive Medline search for
relevant literature.
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RESULTS: In the base case, a pharmaceutical care beneﬁt
in the elderly population would cost $6312 (year 2000
prices) per life year saved-highly cost-effective. Aside
from the number of deaths that are medication-related,
no individual variations in parameters raised the cost-
effectiveness ratio above $10,982 per life year saved.
CONCLUSION: Despite data limitations, pharmaceuti-
cal care appears to be a highly cost effective augmenta-
tion to a Medicare drug beneﬁt program. This result is
insensitive to model parameter changes. This model is
conservative in that it does not include ongoing beneﬁts
from medication monitoring, or increased elderly drug
utilization and polypharmacy as the Medicare drug
program is phased in.
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OBJECTIVES: This study focuses on the use of a new
analytical tool, the Generic Prescribing Index (GPI), as a
tool for healthcare cost containment. An illustrative cost
analysis was performed using a statewide Medicaid data-
base to demonstrate the utility of the GPI concept. The
GPI is the ratio between the total number of generic pre-
scriptions within a therapeutic class divided by the total
number of prescriptions within the therapeutic class.
METHODS: A retrospective data analysis was conducted
to analyze the prescribing of cimetidine, ranitidine, famo-
tidine, and nizatidine statewide to assess the ﬁnancial
impact of brand name prescribing for H2 blockers. H2
blocker prescription data for SFY 2000 came from the
state Medicaid database. Descriptive statistics were cal-
culated. The GPI was calculated for the state, each region
of the state, and each primary care physician in the 
Medicaid program.
RESULTS: The GPI for the state was 0.4319, meaning
approximately 43% of H2 blockers prescribed were
generic products. In over 20 counties, the brand name
famotidine prescribing rate was over 50%. The use of
brand name famotidine resulted in over $2 million in
added expenditures (during the study period), which
could have been freed up for alternative uses if ranitidine
had become the medication of choice for H2 blocker 
prescribing.
CONCLUSION: The Generic Prescribing Index provides
a model for future use in other therapeutic classes (e.g.,
proton pump inhibitors, ace inhibitors) with similar
potential for therapeutic substitution. It is an inexpen-
sive method to analyze prescription drug patterns and
perform economic analysis. It may be useful in develop-
ing prior authorization programs and promoting cost-
effective prescribing. The GPI information may be used
in counter-detailing programs to illustrate the importance
of selecting a medication with a generic substitute within
a therapeutic class, if appropriate for the patient.
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IMPACT OF SELECTED CONDITIONS ON THE
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OBJECTIVE: To explore whether payment mechanisms
for the treatment of conditions often reimbursed outside
of the health-care industry could beneﬁt by incorporation
of severity or case-mix adjustments.
METHODS: Data were culled from a fully integrated
medical and pharmacy claims database, and were
obtained on acute treatment episodes for all skin and soft
tissue injuries, major/minor trauma, and fractures over a
two-year period (N = 4.8 million). Episodes were strati-
ﬁed by type; selected comorbidities (arthritis, diabetes,
osteoporosis) and complications (device/graft failure,
post-operative infection or hemorrhage) thought to
potentially affect recovery and hence total utilization and
costs were identiﬁed. Measures of interest were estimated
at an episode level, and included total episode duration
(in days), number of services provided, and total billed
charges. Measures were analyzed using techniques of
multiple linear regression; in addition to markers for 
complications and comorbidities, independent variables
included age, gender, and geographic region.
RESULTS: While absolute measures of episode duration,
utilization, and charges increased with age for patients
with comorbidity or complication diagnoses, the inde-
pendent effects of these conditions decreased in older 
age groups; in particular, effect sizes in patients aged 
≥ 65 years were minimal. Among individual conditions
for patients aged <65 years, arthritis and osteoporosis
were generally found to signiﬁcantly increase episode
duration but not utilization or costs. In contrast, the
impact of diabetes on adjusted mean episode duration
(139.5 vs. 74.8 days with and without diabetes respec-
tively), number of services (16.8 vs. 9.9, p < .001), and
total episode charges ($3,473 vs. $1,482) was signiﬁcant
(p < .001), using uncomplicated trauma as an example.
The effects of post-operative complications were even
more pronounced (e.g., $6,908 vs. $1,482 for uncompli-
cated trauma episodes).
CONCLUSIONS: These ﬁndings suggest that accident
and injury payments should adjust for the impact of 
post-operative complications and diabetes on treatment
duration, intensity, and costs.
